Replimune, Inc.
Clinical trials sponsored by Replimune, Inc., explained in plain language.
Biopharmaceutical company developing oncolytic immunotherapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Genetically modified virus takes on tough melanoma
Disease control Recruiting nowThis Phase 3 trial tests whether a genetically modified herpes virus (vusolimogene oderparepvec) combined with the immunotherapy drug nivolumab can help people with advanced melanoma that has stopped responding to prior treatments. About 400 participants will receive either the v…
Phase: PHASE3 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for rare eye cancer: experimental combo aims to shrink tumors and extend life
Disease control Recruiting nowThis study tests whether a new drug called RP2, given with nivolumab, works better than the current standard combination (ipilimumab plus nivolumab) for people with metastatic uveal melanoma, a rare eye cancer that has spread. About 280 adults who have not had prior immunotherapy…
Phase: PHASE2, PHASE3 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Cold virus turned cancer killer: new hope for liver cancer patients?
Disease control Recruiting nowThis study tests a genetically modified herpes virus (RP2) that infects and destroys cancer cells while also stimulating the immune system. It is given alone or together with standard drugs (bevacizumab, atezolizumab, or durvalumab) to 60 adults with advanced liver or bile duct c…
Phase: PHASE2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Researchers track Long-Term risks of viral cancer therapy
Knowledge-focused Recruiting nowThis study watches 50 people who already received a replimune oncolytic immunotherapy for cancers like melanoma or liver cancer. The goal is to check for any delayed side effects over 5 years. No new treatment is given—just regular check-ins to see how patients are doing.
Sponsor: Replimune, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC